-
Product Insights
Fragile X Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Fragile X Syndrome Clinical Trial Report Overview A total of 110 fragile X syndrome clinical trials were conducted as of March 2024. The fragile X syndrome clinical trial report provides a comprehensive understanding of the fragile X syndrome clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ARCT-810 in Ornithine-Transcarbamylase Deficiency
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ARCT-810 in Ornithine-Transcarbamylase Deficiency report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ARCT-810 in Ornithine-Transcarbamylase Deficiency Drug Details: ARCT-810 is under development for the...
-
Product Insights
NewNet Present Value Model: Arcturus Therapeutics Holdings Inc’s ARCT-810
Empower your strategies with our Net Present Value Model: Arcturus Therapeutics Holdings Inc's ARCT-810 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Cystic Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Cystic Fibrosis - Drugs In Development, 2023’, provides an overview of the Cystic Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cystic Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Pandemic Influenza – Drugs In Development, 2023
Global Markets Direct’s, ‘Pandemic Influenza - Drugs In Development, 2023’, provides an overview of the Pandemic Influenza pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pandemic Influenza, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BSI-060T in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BSI-060T in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BSI-060T in Colorectal Cancer Drug Details: BSI-060T is under development for...
-
Product Insights
Net Present Value Model: Arcturus Therapeutics Holdings Inc’s ARCT-810
Empower your strategies with our Net Present Value Model: Arcturus Therapeutics Holdings Inc's ARCT-810 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Arcturus Therapeutics Holdings Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Arcturus Therapeutics Holdings Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...